News & Trends - Biotechnology

Government finalises UQ-CSL COVID-19 vaccine agreement

Health Industry Hub | October 12, 2020 |
[Total: 1    Average: 5/5]

Biotech News: The Australian Government is investing a total of $2.3 billion to support home-grown researchers and manufacturers to develop and produce a COVID-19 vaccine, while engaging in strategic international partnerships to support access for Australia and our region.

Under its COVID-19 Vaccine and Treatment Strategy, the Australian Government is investing $1.7 billion to pre-order 84.8 million doses of vaccine with leading Australian manufacturer CSL Limited (Seqirus) and UK-based AstraZeneca.

On 7 September 2020, the Australian Government announced that should promising trials prove successful for the University of Oxford/Astra Zeneca and the University of Queensland vaccine candidates, more than 80 million doses of the two potential COVID-19 vaccines would be made available for the Australian population, almost entirely manufactured in Melbourne. 

This followed from the execution of a binding Heads of Terms between the Australian Government and CSL/Seqirus for the University of Queensland vaccine candidate (451).

The Government has now entered a final supply agreement with CSL/Seqirus around the supply of 51 million doses of the University of Queensland (UQ)-CSL COVID-19 vaccine candidate, including key terms to support clinical and technical development activities for the vaccine candidate.

Phase IIb/III trials of the UQ vaccine candidate are scheduled to start in early December 2020 in numerous countries and over more than 100 sites. The study will evaluate efficacy, immunogenicity and safety in adults aged 18 years and above.

The Australian Government has also joined the COVAX facility, providing access to a large portfolio of COVID-19 vaccine candidates and manufacturers across the world. The Government’s upfront payment of $123.2 million guarantees we receive offers to purchase a number of vaccine candidates from around the world as they become available, meeting safety and effectiveness standards.

This is Australia’s second commitment to the COVAX facility, with $80 million donated in August to the COVAX Advance Market Commitment – a collaborative effort to provide doses to developing countries, enabling more countries to protect their most vulnerable groups.

Australia’s contribution supports a global coordination effort to ensure equitable and affordable access to COVID-19 vaccines, which is essential to reinvigorate the global economy.

You may also like Budget delivers significant news for R&D

About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech News - Medtronic recognised in the 2020 AFR BOSS most innovative health companies list

Medtronic recognised in the 2020 AFR BOSS most innovative health companies list

Health Industry Hub | October 23, 2020 |

MedTech News: Medtronic Australasia was proud to be recognised as one of Australia and New Zealand’s most innovative companies –ranking […]


News & Trends - Biotechnology

Biotech News - Ground-breaking COVID-19 test to not only identify virus but whether patient is infectious

Ground-breaking COVID-19 test to not only identify virus but whether patient is infectious

Health Industry Hub | October 23, 2020 |

Please log in to Health Industry Hub to view this content.

News & Trends - Pharmaceuticals

Pharma News - GSK confirms manufacturing site closure at end of 2022

GSK confirms manufacturing site closure at end of 2022

Health Industry Hub | October 22, 2020 |

Pharma News: In July 2020, GSK Australia announced to employees and stakeholders that the Boronia site in VIC would exit […]


Leadership & Management

Leadership Management Qualities - Creating the ‘light bulb moment’ on unconscious bias

Creating the ‘light bulb moment’ on unconscious bias

Health Industry Hub | October 21, 2020 |

Please log in to Health Industry Hub to view this content.